21
7/28/2019 2-Chirenje Pelvic Inflammatory Disease.pdf http://slidepdf.com/reader/full/2-chirenje-pelvic-inflammatory-diseasepdf 1/21 PID and Its Sequelae Z Mike Chirenje MD FRCOG [email protected]

2-Chirenje Pelvic Inflammatory Disease.pdf

Embed Size (px)

Citation preview

Page 1: 2-Chirenje Pelvic Inflammatory Disease.pdf

7/28/2019 2-Chirenje Pelvic Inflammatory Disease.pdf

http://slidepdf.com/reader/full/2-chirenje-pelvic-inflammatory-diseasepdf 1/21

PID and Its Sequelae

Z Mike Chirenje MD FRCOG

[email protected]

Page 2: 2-Chirenje Pelvic Inflammatory Disease.pdf

7/28/2019 2-Chirenje Pelvic Inflammatory Disease.pdf

http://slidepdf.com/reader/full/2-chirenje-pelvic-inflammatory-diseasepdf 2/21

Physiology of Vag Discharge

What controls contents of vaginal

environment in a woman of reproductive

age?

Micro-environment vagina-cervical

compartment is controlled by lactobacillus

species to maintain ph acid <4.5)

Page 3: 2-Chirenje Pelvic Inflammatory Disease.pdf

7/28/2019 2-Chirenje Pelvic Inflammatory Disease.pdf

http://slidepdf.com/reader/full/2-chirenje-pelvic-inflammatory-diseasepdf 3/21

Vaginal Discharge and STI

• What is the prevalence of STI(HIV,GC,CT,TV,Syphilis) among womenpresenting with abnormal vaginal

discharge• How much does Candida albicans and BV

contribute to this prevalence in abnormaldischarge?

• Candidiasis and BV are not necessarilySTI but associated with sexual intercourse

Page 4: 2-Chirenje Pelvic Inflammatory Disease.pdf

7/28/2019 2-Chirenje Pelvic Inflammatory Disease.pdf

http://slidepdf.com/reader/full/2-chirenje-pelvic-inflammatory-diseasepdf 4/21

Selected Participant Characteristics

in HPTN 035 Study (N=3099)

Percent of Participants with Infection

Diagnosed During Screening

Infection Harare Site (600) All Sites Combined

Bacterial vaginosis byNugent Score (7-10)

27% 36%

Chlamydia 3% 3%

Gonorrhea <1% 1%

Syphilis 2% 2%

Trichomoniasis 4% 7%

Herpes simplex virus-2 34% 46%

Page 5: 2-Chirenje Pelvic Inflammatory Disease.pdf

7/28/2019 2-Chirenje Pelvic Inflammatory Disease.pdf

http://slidepdf.com/reader/full/2-chirenje-pelvic-inflammatory-diseasepdf 5/21

Cervicitis

•  Anatomically, the cervix has 2 distinct

portions namely ectocervix that merges

into upper vaginal wall and endocervix that

merges into endometrial gland lining

• Cervicitis is inflammation of endocervical

mucosa

• Most commonly caused by an STI

Page 6: 2-Chirenje Pelvic Inflammatory Disease.pdf

7/28/2019 2-Chirenje Pelvic Inflammatory Disease.pdf

http://slidepdf.com/reader/full/2-chirenje-pelvic-inflammatory-diseasepdf 6/21

Page 7: 2-Chirenje Pelvic Inflammatory Disease.pdf

7/28/2019 2-Chirenje Pelvic Inflammatory Disease.pdf

http://slidepdf.com/reader/full/2-chirenje-pelvic-inflammatory-diseasepdf 7/21

Cervicitis

• Chlamydia trachomatis and N. gonorrhea

cause muco-purelent discharge

• Herpes simples virus and T.vaginalis

cause a ectocervicitis

• ICC,foreign body,trauma,other viral

infections, schistosomiasis are less

frequent causes

Page 8: 2-Chirenje Pelvic Inflammatory Disease.pdf

7/28/2019 2-Chirenje Pelvic Inflammatory Disease.pdf

http://slidepdf.com/reader/full/2-chirenje-pelvic-inflammatory-diseasepdf 8/21

Complications of cervical infections

• Cervix is entry to upper genital tract

(normally sterile if there is no anatomic

disruption)

• Can result in ascending infection PID

• Neonatal infection (CT,GC, Herpes)

Reinfection of original partner or newpartner 

• Disseminated GC

Page 9: 2-Chirenje Pelvic Inflammatory Disease.pdf

7/28/2019 2-Chirenje Pelvic Inflammatory Disease.pdf

http://slidepdf.com/reader/full/2-chirenje-pelvic-inflammatory-diseasepdf 9/21

Gonorrhoea in F

• 5-10 days incubation (20-40% sub-clinical)

• Cervicitis,urethritis,pharyngitis,conjuctivitis

and proctitis

• Gonococcal cervicitis is often

asymptomatic

Neisseria gonorrhoea is gram negdiplococci under the microscope

Page 10: 2-Chirenje Pelvic Inflammatory Disease.pdf

7/28/2019 2-Chirenje Pelvic Inflammatory Disease.pdf

http://slidepdf.com/reader/full/2-chirenje-pelvic-inflammatory-diseasepdf 10/21

Chlamydia

• Typically presents as muco-purelent

discharge, in a cervix that exhibits contact

bleeding and has oedema

• 1-3 weeks incubation, often subclinical

• Is an intracellular bacterium detected by

DNA metods

Page 11: 2-Chirenje Pelvic Inflammatory Disease.pdf

7/28/2019 2-Chirenje Pelvic Inflammatory Disease.pdf

http://slidepdf.com/reader/full/2-chirenje-pelvic-inflammatory-diseasepdf 11/21

Gonorrhoea and chlamydia

trachomatis

= colonizes endocervix, urethra, rectum, pharynx.

= should be sampled for culture or DNA probe

testing, PCR, LCR.

= 10 to 20% develop PID if untreated.

Page 12: 2-Chirenje Pelvic Inflammatory Disease.pdf

7/28/2019 2-Chirenje Pelvic Inflammatory Disease.pdf

http://slidepdf.com/reader/full/2-chirenje-pelvic-inflammatory-diseasepdf 12/21

PID

• Is an upper genital tract infection

(endometritis,salpingitis,oophoritis and/or 

pelvic peritonitis)

• The infection occurs from ascending

genital infection unrelated to child birth or 

surgical manipulations

• Clinically divided into sub-clinical, mild

(most cases) severe,

Page 13: 2-Chirenje Pelvic Inflammatory Disease.pdf

7/28/2019 2-Chirenje Pelvic Inflammatory Disease.pdf

http://slidepdf.com/reader/full/2-chirenje-pelvic-inflammatory-diseasepdf 13/21

PID

• Complications of untreated PID include:

Pelvic abscess, severe peritonitis

Infertility from blocked fallopian tubesand pelvic adhesions

Chronic pelvic pain and dysparunia

Ectopic pregnancy that can rupture andcause death

Page 14: 2-Chirenje Pelvic Inflammatory Disease.pdf

7/28/2019 2-Chirenje Pelvic Inflammatory Disease.pdf

http://slidepdf.com/reader/full/2-chirenje-pelvic-inflammatory-diseasepdf 14/21

 Aetiology of PID

• GC and CT are the most commonaetiological agents

• Several other anaerobic bacterial species

found in vagina (bacteriodes,anaerobicGm positive cocci,E.coli, facultative Gmneg rods and Mycoplasma hominis) areusually accompanying pathogens

• Typically a woman with PID has 2 or moreof these pathogens

Page 15: 2-Chirenje Pelvic Inflammatory Disease.pdf

7/28/2019 2-Chirenje Pelvic Inflammatory Disease.pdf

http://slidepdf.com/reader/full/2-chirenje-pelvic-inflammatory-diseasepdf 15/21

PID

• Because the infection is often of mixed

pathogens that we may not be able to

detect precise microbiological species, a

broad spectrum of antibiotics iscornerstone to managing these women

Page 16: 2-Chirenje Pelvic Inflammatory Disease.pdf

7/28/2019 2-Chirenje Pelvic Inflammatory Disease.pdf

http://slidepdf.com/reader/full/2-chirenje-pelvic-inflammatory-diseasepdf 16/21

Clinical Features of PID

• LAP is common presentation that must be

differentiated from women with ectopic

pregnancy,appendecitis complications of 

pregnancy like miscarriage

• Dyspareunia

• Vaginal discharge

•  Abnormal Uterine bleeding

• Others (fever,nausea/vomoting)

Page 17: 2-Chirenje Pelvic Inflammatory Disease.pdf

7/28/2019 2-Chirenje Pelvic Inflammatory Disease.pdf

http://slidepdf.com/reader/full/2-chirenje-pelvic-inflammatory-diseasepdf 17/21

PID

• Clinical symptoms and signs are variableand therefore a good history and physicalexam are critical in making a correct DX

• LAP, cervical exitation tenderness,adnexae tenderness, rebound tendernessmay be present in a woman with abnormalvaginal discharge

•  Adnexae/pelvic mass that is tender maybe a significant finding

Page 18: 2-Chirenje Pelvic Inflammatory Disease.pdf

7/28/2019 2-Chirenje Pelvic Inflammatory Disease.pdf

http://slidepdf.com/reader/full/2-chirenje-pelvic-inflammatory-diseasepdf 18/21

PID

•  All patients with severe PID must be

hospitalized to allow IV antibiotic therapy

and response to treatment (Temp chart

and clinical response of lower/pelvicexam)

• In general, clinicians would rather over 

treat than under treat women suspected tohave PID

Page 19: 2-Chirenje Pelvic Inflammatory Disease.pdf

7/28/2019 2-Chirenje Pelvic Inflammatory Disease.pdf

http://slidepdf.com/reader/full/2-chirenje-pelvic-inflammatory-diseasepdf 19/21

PID in HIV positive

• Several studies have found seroprevalence of 

HIV in hospitalized PID patients.

• Clinical presentation is observed to be more

severe in HIV positive compared to HIV negative

(Cohen 1998, Kenyan study) particularly withlower wbc count.

Page 20: 2-Chirenje Pelvic Inflammatory Disease.pdf

7/28/2019 2-Chirenje Pelvic Inflammatory Disease.pdf

http://slidepdf.com/reader/full/2-chirenje-pelvic-inflammatory-diseasepdf 20/21

• Tubo-ovarian abscess, CMV, TB, TV are

reported in African studies to be more

common in HIV infected women (Margolis

Cape Town 1992, Moodley Durban 2002).

Page 21: 2-Chirenje Pelvic Inflammatory Disease.pdf

7/28/2019 2-Chirenje Pelvic Inflammatory Disease.pdf

http://slidepdf.com/reader/full/2-chirenje-pelvic-inflammatory-diseasepdf 21/21

• Microbiology of infection and response tostandard AB regimens are similar to HIVuninfected women.

•  Aggressive parenteral regimen whenmanaging HIV infected women with PID is

recommended